arrow
F

Fady I. Malik

Harvard University
H指数:40
被引数:6,783

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Safety and Efficacy of Aficamten in Patients With Nonobstructive Hypertrophic Cardiomyopathy: A 96-Week Analysis From FOREST-HCM

Aficamten在非梗阻性肥厚型心肌病患者的安全性与有效性:FOREST-HCM研究96周分析

2025-09-280
OAAI
Low Incidence of Atrial Fibrillation in Patients with Obstructive HCM Treated with Aficamten: An Analysis from the REDWOOD-HCM, SEQUOIA-HCM and FOREST-HCM Trials

梗阻性肥厚型心肌病患者使用Aficamten治疗后房颤发生率低:REDWOOD-HCM、SEQUOIA-HCM和FOREST-HCM试验的分析

2025-08-310
OAAI
Serum magnesium and outcomes in heart failure with reduced ejection fraction: the GALACTIC-HF trial

血清镁与射血分数降低的心力衰竭的结局:GALACTIC-HF试验

2025-08-011
OAAI
Hospitalizations as an outcome measure in COURAGE-ALS

COURAGE-ALS研究中以住院治疗作为结局指标

2025-06-120
OA
Reldesemtiv in Amyotrophic Lateral Sclerosis: Results From the COURAGE-ALS Randomized Clinical Trial

利德尔西米夫在肌萎缩侧索硬化症中的应用:COURAGE-ALS随机临床试验的结果

2025-05-010
PRE
Efficacy of aficamten in patients with obstructive hypertrophic cardiomyopathy and mild symptoms: results from the SEQUOIA-HCM trial

阿菲坎坦在梗阻性肥厚型心肌病伴轻度症状患者中的疗效:SEQUOIA-HCM试验结果

2025-05-012
OAAI
Discovery of Nelutroctiv (CK-136), a Selective Cardiac Troponin Activator for the Treatment of Cardiovascular Diseases Associated with Reduced Cardiac Contractility (vol 67, pg 7825, 2024)
2024-12-260
OAAI
Efficacy and Safety of Aficamten in Patients Guideline-Eligible for Septal Reduction Therapy in the FOREST-HCM Trial

Aficamten在FOREST-HCM试验中,对符合室间隔减容治疗指南适应证患者的疗效与安全性

2024-11-120
PRE
Efficacy and Safety of Aficamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Results From the REDWOOD-HCM Trial, Cohort 4

Aficamten在症状性非梗阻性肥厚型心肌病中的疗效和安全性: 来自REDWOOD-HCM试验的结果,队列4

2024-11-017
OAAI
Aficamten and Cardiopulmonary Exercise Test Performance: A Substudy of the SEQUOIA-HCM Randomized Clinical Trial
2024-11-011
PRE
Cardiac biomarkers and effects of aficamten in obstructive hypertrophic cardiomyopathy: the SEQUOIA-HCM trial

心脏生物标志物及阿非卡坦在梗阻性肥厚型心肌病中的疗效:SEQUOIA-HCM试验

2024-09-013
OAAI
Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM

Aficamten在症状性梗阻性肥厚型心肌病中的剂量和安全性: 来自sequoia-hcm的结果

2024-08-064
OAAI